Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.44 |
| ▸ | HTR1A | P08908 | 3/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20158435 | 0.87 | HSD11B1 (0.47) | HSD11B1HSD11B2SLC6A2HTR1ASLC6A3 | |
| SCHEMBL20147415 | 0.84 | SLC6A4 (0.53) | SLC6A4GRIN1GRIN2B | |
| SCHEMBL14983623 | 0.84 | HRH3 (0.49) | SLC6A2HTR1ASLC6A3 | |
| SCHEMBL20068824 | 0.81 | GRIN1 (0.41) | SLC6A2HTR1ASLC6A3SLC6A4GRIN1 | |
| SCHEMBL20068827 | 0.81 | SSTR4 (0.44) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL10261794 | 0.81 | SLC6A2 (0.47) | HSD11B1HSD11B2SLC6A2HTR1ASLC6A3 | |
| SCHEMBL3825759 | 0.81 | SCN9A (0.48) | HSD11B1HSD11B2SLC6A2HTR1ASLC6A3 | |
| SCHEMBL25807458 | 0.80 | SLC6A4 (0.47) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL17476167 | 0.77 | SLC6A2 (0.47) | HSD11B1HSD11B2SLC6A2HTR1ASLC6A3 | |
| SCHEMBL14873929 | 0.77 | SLC6A2 (0.47) | HSD11B1HSD11B2SLC6A2HTR1ASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| WO-2018071454-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ANDREWS STEVEN W (US) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | HSD11B1 2886/4885HSD11B2 2994/4885SLC6A2 4053/4885 |
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | HSD11B1 2886/4885HSD11B2 2994/4885SLC6A2 4053/4885 |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | HSD11B1 2886/4885HSD11B2 2994/4885SLC6A2 4053/4885 |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | HSD11B1 2886/4885HSD11B2 2994/4885SLC6A2 4053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.